Grabnar I, Bogataj M, Belic A, Logar V, Karba R, Mrhar A
Faculty of Pharmacy, University of Ljubljana, Askerceva 7, SI-1000 Ljubljana, Slovenia.
Int J Pharm. 2006 Sep 28;322(1-2):52-9. doi: 10.1016/j.ijpharm.2006.05.026. Epub 2006 May 19.
Intravesical administration of cytotoxic agents is commonly used in urological practice for treatment of superficial bladder cancer. The leading motive is optimisation of drug delivery near the site of action and reduction of systemic toxicity. Bladder pharmacokinetics is complicated by several mechanisms. The objectives of this work were to develop a kinetic model of drug distribution in the bladder wall following intravesical instillation and to study the effect of various parameters on tissue and systemic drug exposure and explore the potential benefits of permeability enhancing effects of chitosan (CH) and polycarbophil (PC) through simulation. Key elements of the model are variable urinary drug concentration due to urine formation and voiding, biphasic diffusion in the bladder tissue and systemic absorption. Model parameters were estimated from bladder-tissue concentration profiles obtained in previous in vitro experiments with pipemidic acid (PPA) as a model drug. The results support further investigations on application of CH and PC in intravesical drug delivery. Both polymers increase permeability of the bladder wall by diffusion enhancement in the urothelium and presumably by improving the contact with the bladder surface. The developed mathematical model could serve for optimisation of intravesical drug delivery and future development of intravesical drug delivery systems.
膀胱内给予细胞毒性药物在泌尿外科实践中常用于治疗浅表性膀胱癌。主要目的是优化药物在作用部位附近的递送并降低全身毒性。膀胱的药代动力学因多种机制而变得复杂。这项工作的目标是建立膀胱内灌注后药物在膀胱壁中分布的动力学模型,研究各种参数对组织和全身药物暴露的影响,并通过模拟探索壳聚糖(CH)和聚卡波非(PC)的渗透增强作用的潜在益处。该模型的关键要素包括由于尿液生成和排尿导致的可变尿液药物浓度、膀胱组织中的双相扩散以及全身吸收。模型参数是根据先前以吡哌酸(PPA)作为模型药物的体外实验获得的膀胱组织浓度曲线估算得出的。结果支持对CH和PC在膀胱内药物递送中的应用进行进一步研究。两种聚合物都通过增强尿路上皮的扩散以及可能通过改善与膀胱表面的接触来增加膀胱壁的通透性。所建立的数学模型可用于优化膀胱内药物递送以及膀胱内药物递送系统的未来开发。